Recruiting Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment NCT07281833 Conditions Advanced Breast Cancer, Breast Cancer, Breast Diseases, +14 more Locations Institut Jules Bordet — Anderlecht, Belgium CHC MontLegia — Liège, Belgium St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie — Cologne, North Rhine-Westphalia, Germany Universitätsklinikum Essen — Essen, North Rhine-Westphalia, Germany View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812 Conditions Abemaciclib, Breast Adenocarcinoma, Breast Cancer, +46 more Locations Centro di Riferimento Oncologico IRCCS — Aviano, Italy Azienda Socio Sanitaria Territoriale degli Spedali Civili — Brescia, Italy Humanitas Istituto Clinico Catanese — Catania, Italy ASST Lariana - Ospedale Sant'Anna — Como, Italy View all 24 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC NCT04448886 Conditions Breast Diseases, Breast Neoplasms, HER2-negative Breast Cancer, +7 more Locations Emory University/Winship Cancer Institute — Atlanta, Georgia, United States University of Chicago Medical Center — Chicago, Illinois, United States Dana Farber Cancer Institute — Boston, Massachusetts, United States DFCI @ Foxborough — Foxborough, Massachusetts, United States View more locations Show fewer locations Loading locations... View Trial Details
